A quarter century ago, Colin Angle set out with two MIT colleagues with ambitions of putting walking robots in space. Today, Angle, CEO of iRobot, has settled for the world's best-selling robotic vacuum cleaner, the Roomba. It's not space, but, with about 16 million sold over the last 15 years, the Roomba is one of the best-selling consumer robots of any type ever.

Angle's message for commercial robot-makers: go short cool and complex; go long rugged, reliable and simple.

It's germane right now: Last Friday, Alphabet sold off Boston Dynamics, one of the world's most advanced robot-makers. The reasons: Boston Dynamics' walking, jumping robots were agile and cool, but contained no machine learning software, and, analysts say, had difficulty finding a commercial market.

That may or may not be true: Softbank, Boston Dynamics' purchaser, clearly thinks Alphabet is wrong about the company's commerciality. But, for all the hoopla over robots, not many have penetrated the consumer market yet. "Here we are, in 2017, and we're just about none of the way to achieving the potential that robots are going to play ultimately in our world," Angle told Axios at iRobot's headquarters in Bedford, Massachusetts.

Getting to vacuums was a journey: "My early days," Angle said, "was all building legged robots, and, you know, I think part of what — the reason why I ended up being so focused on practical robotics — is the transition I made from wanting to build Commander Data from Star Trek, or if not that at least legged, walking robots that could go explore other planets." He went on:

"For my master's thesis at MIT I built a robot so complicated that it just collapsed under its own crushing, like, complexity. You know, it had six legs. Each leg had four degrees of freedom. Each leg had its own microprocessor. There was hundreds of sensors on this robot, and it just _ I think the mean time between failures, was about seven minutes, and the promise of the legs was never realized."

That's where Angle learned his lesson: "Don't add anything to a robot design that doesn't need to be there. And so what we can we take out of the robot to make it more rugged, more reliable, even if it would be cool to add something."

Go deeper

Updated 15 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Global: Total confirmed cases as of 6:30 p.m. ET: 20,177,521 — Total deaths: 738,716 — Total recoveries: 12,400,156Map.
  2. U.S.: Total confirmed cases as of 6:30 p.m. ET: 5,130,784 — Total deaths: 164,603 — Total recoveries: 1,670,755 — Total tests: 62,513,174Map.
  3. States: Georgia reports 137 coronavirus deaths, setting new daily record Florida reports another daily record for deaths.
  4. Health care: Trump administration buys 100 million doses of Moderna's coronavirus vaccine.
  5. Business: Moderna reveals it may not hold patent rights for vaccine.
  6. Sports: Big Ten scraps fall football season.

Voters cast ballots in Minnesota, Georgia, Connecticut, Wisconsin and Vermont

Photo: Spencer Platt/Getty Images

Primary elections are being held on Tuesday in Minnesota, Georgia, Connecticut, Vermont and Wisconsin.

The big picture: Georgia and Wisconsin both struggled to hold primaries during the coronavirus pandemic, but are doing so again — testing their voting systems ahead of the general election. Rep. Ilhan Omar (D-Minn.) is facing a strong challenger as she fights for her political career. In Georgia, a Republican primary runoff pits a QAnon supporter against a hardline conservative.

44 mins ago - Health

Trump administration buys 100 million doses of Moderna's vaccine

A volunteer in Moderna's vaccine clinical trial receives a shot. Photo: Paul Hennessy/NurPhoto via Getty Images

The U.S. government has agreed to buy 100 million doses of Moderna's experimental coronavirus vaccine for $1.5 billion, or $15 per dose.

Why it matters: The Trump administration, through Operation Warp Speed, has now bought initial batches of vaccines from Moderna, GlaxoSmithKline and Sanofi, Pfizer, Novavax, Johnson & Johnson and AstraZeneca before knowing whether they are safe and effective. The federal government also appears to own some of the patent rights associated with Moderna's vaccine.